This article was originally published in The Gray Sheet
Raises $3.5 mil. in first round of venture capital financing to fund development of DNA-based diagnostic tests using "ultraminiaturized silicon chips inlaid with artificial DNA to detect specific gene sequences," the firm says in a March 15 release. Investors include Enterprise Partners, Kleiner Perkins Caufield & Byers and Nanogen Chairman and CEO Howard Birndorf, who have "committed to additional funding as the company reaches certain milestones," the firm says.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.